These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20410142)

  • 1. Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida.
    Sierra F
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):577-9. PubMed ID: 20410142
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
    Sharp ZD; Strong R
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapamycin: the cure for all that ails.
    Hasty P
    J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 5. [Indications of mTOR inhibitors in liver transplantation].
    Calmus Y; Dharancy S
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
    [No Abstract]   [Full Text] [Related]  

  • 6. TOR-driven aging: speeding car without brakes.
    Blagosklonny MV
    Cell Cycle; 2009 Dec; 8(24):4055-9. PubMed ID: 19923900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rapamycin on lifespan in Drosophila.
    Harrison B; Tran TT; Taylor D; Lee SD; Min KJ
    Geriatr Gerontol Int; 2010 Jan; 10(1):110-2. PubMed ID: 20102391
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.
    Osman B; Doller A; Akool el-S; Holdener M; Hintermann E; Pfeilschifter J; Eberhardt W
    Cell Signal; 2009 Dec; 21(12):1806-17. PubMed ID: 19666112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.
    Koehl GE; Spitzner M; Ousingsawat J; Schreiber R; Geissler EK; Kunzelmann K
    Oncogene; 2010 Mar; 29(10):1553-60. PubMed ID: 19966863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible severe synovitis associated with everolimus.
    Kato TS; Sasaoka T; Wada K; Nakatani T; Komamura K
    J Heart Lung Transplant; 2010 Jun; 29(6):710-1. PubMed ID: 20188596
    [No Abstract]   [Full Text] [Related]  

  • 12. mTOR inhibitor-associated dermatologic and mucosal problems.
    Campistol JM; de Fijter JW; Flechner SM; Langone A; Morelon E; Stockfleth E
    Clin Transplant; 2010; 24(2):149-56. PubMed ID: 20236129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroscience. A glutamate pathway to faster-acting antidepressants?
    Cryan JF; O'Leary OF
    Science; 2010 Aug; 329(5994):913-4. PubMed ID: 20724626
    [No Abstract]   [Full Text] [Related]  

  • 14. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
    Huynh H
    Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
    Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR?
    Rule S
    Am J Hematol; 2010 May; 85(5):313-4. PubMed ID: 20425793
    [No Abstract]   [Full Text] [Related]  

  • 18. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
    Soll C; Clavien PA
    Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.